Bioxodes is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics to prevent thrombotic events and thrombo-inflammatory diseases.
Bioxodes takes advantage of its deep understanding of the thrombotic processes to design novel product candidates with an aim to achieve anticoagulation without hemorrhagic risk.
In parallel, Bioxodes is developing a pipeline of drug candidates targeting chronic inflammatory diseases.
This innovative pipeline includes a clinical-stage program for the prevention of acute thrombo-inflammatory processes. The lead product candidate, Ir-CPI, exhibits a unique mechanism of action by targeting coagulation factors (FXIIa & FXIa), neutrophil activation and Neutrophil Extracellular Trap (NET) release, key driver components of thrombo-inflammatory processes involved in various diseases such as stroke, rheumatoid arthritis, lupus and sepsis.
In addition, Bioxodes has recently completed with success the active phase of its First-in-Human study performed in healthy adult volunteers with Ir-CPI.
Bioxodes is located in the Brussels South Charleroi Biopark, Belgium.